Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio (Nasdaq: VOR) announced inducement grants on November 2025 and March 23, 2026, to eight newly hired employees under its 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) announced inducement grants on November 2025 and March 23, 2026, to eight newly hired employees under its 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The Compensation Committee granted stock options to purchase an aggregate of 215,700 shares and 46,235 RSUs. Options carry ten-year terms with exercise prices of $7.95 to $24.11, equal to closing prices on grant dates. Options vest over four years (25% after 12 months, then monthly for 36 months); RSUs vest over four years (25% after 12 months, then quarterly for 36 months).

Argus Mar 24 session

-4.26% close to close Open Argus

Details

News Market Reaction – VOR

In the Mar 24 session, VOR declined 4.26%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement stock options and RSUs granted under Nasdaq Listing Rule 5635(c...

Analysis

This announcement details inducement stock options and RSUs granted under Nasdaq Listing Rule 5635(c)(4) to 8 new employees, totaling 215,700 options and 46,235 RSUs with standard four-year vesting. It follows a period of significant activity, including a $150 million private placement, an effective resale shelf for 13,876,032 shares, and positive Phase 3 updates. Investors may focus on future clinical milestones, additional financing steps, and how ongoing share resales interact with trading liquidity.

Key Figures

Stock options granted: 215,700 shares RSUs granted: 46,235 shares New hires: 8 employees +5 more

Stock options granted

215,700 shares

Aggregate options to newly hired employees under Inducement Plan

RSUs granted

46,235 shares

Aggregate RSUs to newly hired employees under Inducement Plan

New hires

8 employees

Recipients of inducement stock options and RSUs

Option term

10 years

Term of inducement stock options

Exercise price range

$7.95–$24.11 per share

Equal to closing prices on respective grant dates

Option vesting period

4 years

25% after 12 months; remainder monthly over 36 months

RSU vesting period

4 years

25% after 12 months; remainder quarterly over 36 months

Initial vesting cliff

25%

Portion of both options and RSUs vesting after 12 months

Historical Context

5 past events · Latest: Feb 23

5 events

1. Feb 23

   Conference participation

   24h Move

   +13.8%

   Participation in TD Cowen healthcare conference with webcasted company presentation.

2. Jan 06

   Conference participation

   24h Move

   +10.3%

   Presentation and 1x1 investor meetings at J.P. Morgan Healthcare Conference.

3. Dec 23

   Board appointments

   24h Move

   +7.4%

   Addition of RA Capital and Forbion representatives following a $150M PIPE financing.

4. Dec 15

   Private placement

   24h Move

   +8.0%

   Announcement of $150M private placement to fund telitacicept Phase 3 programs.

5. Nov 13

   Earnings & update

   24h Move

   +2.7%

   Q3 2025 results with positive Phase 3 data and strengthened cash position.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"stock options to purchase an aggregate of 215,700 shares ... and restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 46,235 shares of Vor Bio’s common stock to 8 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

The stock options have a ten-year term and exercise prices that range from $7.95 to $24.11 per share, which equal the closing price of Vor Bio’s common stock on the respective grant dates of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did Vor Bio (VOR) announce on March 23, 2026?

Vor Bio granted stock options for 215,700 shares and RSUs for 46,235 shares to eight new hires. According to the company, the grants were made under the 2023 Inducement Plan as material inducements under Nasdaq Listing Rule 5635(c)(4).

What are the exercise prices and terms for the VOR stock options granted in March 2026?

The options have ten-year terms with exercise prices ranging from $7.95 to $24.11 per share. According to the company, those prices equal Vor Bio's closing stock price on each respective grant date.

How do the VOR options and RSUs vest for the March 23, 2026 inducement grants?

Options vest over four years: 25% after 12 months, then monthly over 36 months; RSUs vest 25% after 12 months, then quarterly. According to the company, vesting is subject to continued employment on vesting dates.

How many employees received inducement awards from Vor Bio (VOR) in the disclosed grants?

Eight newly hired employees received the inducement awards in November 2025 and March 23, 2026. According to the company, the grants were intended as material inducements to employment under Nasdaq rules.

Under which plan were Vor Bio's (VOR) March 2026 inducement grants made?

The grants were made under the Vor Biopharma 2023 Inducement Plan. According to the company, award terms are governed by the Inducement Plan and individual award agreements.

Do Vor Bio's (VOR) inducement option prices reflect market value on grant dates?

Yes, the options' exercise prices equal the closing market price on their respective grant dates. According to the company, prices ranged from $7.95 to $24.11 per share based on those closing prices.